Accurate Assessment of Antibody-Mediated Complement-Dependent Cytotoxicity
Accurate Assessment of Antibody-Mediated CDC
Our CDC Reporter-Gene Assays
Didn't find what you were looking for?
We offer products customized to your needs. Our custom iLite® reporter-gene assays can be adapted to almost any target. We also offer custom ELISA plates and other products. In addition, you can take advantage of our service offerings and let us do the work for you.
iLite News
Translating Complex Metabolic Biology into Functional Insight
Read post
Introducing the iLite® Metabolic Panel
Read post
Introducing the new iLite® C3a Assay Ready Cells
Read post
Improved Speed and Accuracy in Immunogenicity Testing
Read post
Transitioning to Second-Generation iLite Cells
Read post
iLite Downloads
Systematic Analysis of Fc Mutations Designed to Modulate Functional Activity
Read post
Therapeutic Antibodies Trimmed with GlycINATOR® Lose Antibody-Dependent Cell-mediated Cytotoxicity
Read post
Quantification of Bispecific Antibody Mediated T-cell Activation
Read post
IL-6 Biology, Inhibitors & COVID-19
Read post
Mechanism-linked Potency Assays Drive Gene Therapy Success
Read post
Addressing the Analytical Gaps in Modern Therapeutic Development
Read post-1.jpg?width=500)
Developing a Customizable Complement-Dependent Cytotoxicity Assay
Read post
Partnering for Success in a New Era of Advanced Therapeutics
Read post
The Immune Response to AAV Gene Therapy
Read post
How to Design Potency Assays for Gene Therapy Projects
Read post
A Cell-Based ADCC Bioassay Comparison
Read post
Quantification of the Neutralizing Antibody Response to Recombinant AAV Vectors
Read post
Svar Complement Assays: Analyzing How Drug Candidates Affect the Complement System
Read post
Assay Development in AAV Therapies: Engineering iLite® Cell Lines for Specific and Analytical Applic...
Read post
Measuring C5a With a Functional Bioassay
Read post
FAQ
What are CDC bioassays?
SVAR Life Science's iLite® CDC Bioassays are cell-based reporter gene assays designed to measure complement-dependent cytotoxicity (CDC), an important mechanism of action for many therapeutic antibodies.
What is complement-dependent cytotoxicity (CDC)?
Complement-dependent cytotoxicity (CDC) is an immune response in which antibodies bind to target cells and activate the complement system, ultimately leading to cell lysis. CDC is a key effector function for several therapeutic antibodies.
Why is CDC testing important in antibody development?
CDC testing helps evaluate whether an antibody can trigger complement-mediated killing of target cells. This information is valuable during antibody screening, characterization, comparability assessments, and potency testing.
What makes iLite® CDC Bioassays different?
iLite® CDC Bioassays are based on iLite® technology, using engineered reporter cells to provide a biologically relevant and mechanism-of-action-reflective assessment of CDC activity. The assays are designed to deliver robust and reproducible results while simplifying workflow.
Can iLite® CDC Bioassays be used for potency testing?
Yes. iLite® CDC Bioassays can support potency testing by providing a functional assessment of complement-mediated biological activity, helping ensure consistent product performance.
How do iLite® CDC Bioassays work?
The assays utilize engineered reporter cells and a luciferase-based readout to quantify complement-mediated effects. The resulting signal provides a convenient way to evaluate antibody-induced CDC activity in vitro.
Are custom CDC bioassays available?
Yes. Svar Life Science can develop custom iLite® reporter-based assays tailored to specific targets and therapeutic programs.
